Starts:

Wednesday, September 21st
4:30pm-6:00pm EDT

Category:

Topical Workshop

Tracks:

Evidence - clinical trials - systematic review - guidelines - implementation science | Evidence, clinical trials, systematic review, guidelines and implementation science

Room

713 B

Back to Sessions List
Register Now!

Clinical Aspects of Tapering Opioids for Chronic Non-Cancer Pain. Presentation of Research Results from UK, US and Canada

The panel will discuss three large research projects related to opioid tapering for chronic non-cancer pain in the UK, US and Canada. Dr. Harbinder Sandhu will show the results of the randomized controlled trial of opioid tapering in the UK (iWotch trial). Dr. Mark Sullivan will discuss the NIDA-funded STRIPE trial which is testing pain self-management training and medication support for opioid taper. Dr. Andrea Furlan will discuss the results of the online opioid self-assessment program (Opioid SAP) among Canadian physicians, nurse practitioners, and medical students.

Presentations

Time
4:30pm EDT–6:00pm EDT

Improving the Wellbeing of Opioid Treated Chronic Pain (I-WOTCH): Results of a UK Randomised Controlled Trial

Tracks: Evidence - Clinical Trials - Systematic Review - Guidelines - Implementation Science, Evidence, Clinical Trials, Systematic Review, Guidelines And Implementation Science
Categories: Topical Workshop
Presented By: Professor Harbinder Sandhu

The I-WOTCH study (a pragmatic multi-centre randomised controlled trial, N=608), set out to test the effectiveness and cost effectiveness of a multicomponent intervention to reduce opioid use. Participants were people living with chronic non-malignant pain. We targeted withdrawal of strong opioids. Two primary outcomes at 12 month follow up are Patient-Reported Outcomes Measurement Information System Pain Interference Short Form (8A)) and opioid use. Secondary outcomes include quality of life (measured by the EQ-5D). In depth process evaluation and qualitative interviews were completed. The main trial analyses are complete and being written up for publication. This will be the first presentation of these important findings.

4:30pm EDT–6:00pm EDT

STRIPE Trial: Pain Self-Management Training and Medication Support for Opioid Taper

Tracks: Evidence - Clinical Trials - Systematic Review - Guidelines - Implementation Science, Evidence, Clinical Trials, Systematic Review, Guidelines And Implementation Science
Categories: Topical Workshop
Presented By: Mark Sullivan

Results from the STRIPE trial, funded by the US National Institute on Drug Abuse, will be presented.  This trial randomized 153 primary care patients taking long-term opioid therapy to telephonic pain coping skills training or usual care. Patients randomized to skills training were offered the option of supported opioid taper at their fourth training session. For those choosing to taper, guidance was provided to their primary care provider about opioid and non-opioid psychotropic medication doses. Primary outcomes were pain (PEG score) and opioid dose (mean daily MED) at 6 and 12 months.

4:30pm EDT–6:00pm EDT

What Physicians Don’t Know That They Don’t Know About Opioid Prescribing

Tracks: Evidence - Clinical Trials - Systematic Review - Guidelines - Implementation Science, Evidence, Clinical Trials, Systematic Review, Guidelines And Implementation Science
Categories: Topical Workshop
Presented By: Dr. Andrea D. Furlan

Dr. Furlan will describe a study conducted with 639 opioid prescribers in Canada that identified areas of knowledge gaps in prescribing opioids for chronic non-cancer pain. Participant scores improved significantly in all six assessment areas of the Online Opioid SAP, most notable in (i) tapering opioids safely and effectively to the lowest possible dose at 51% knowledge increase and, (ii) prevention of opioid use disorder and overdose at 41% knowledge increase from baseline pre-test.

Presenters

Dr. Andrea D. Furlan

Associate Professor, Physiatrist & Senior Scientist
University of Toronto

Professor Harbinder Sandhu

Professor of Health Psychology
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK

Mark Sullivan

Professor
University of Washington